Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Trial to Assess the Safety, Immunological Activity of TroVax Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma

Trial Profile

A Phase II Trial to Assess the Safety, Immunological Activity of TroVax Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 14 Jun 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs MVA 5T4 (Primary) ; Cisplatin; Cobalamin; Dexamethasone; Folic acid; Pemetrexed
  • Indications Malignant-mesothelioma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms SKOPOS
  • Most Recent Events

    • 13 Nov 2015 Status changed from recruiting to completed, according to United Kingdom Clinical Research Network.
    • 13 Nov 2015 Planned End Date changed from 31 Jul 2015 to 27 Aug 2015, according to United Kingdom Clinical Research Network.
    • 09 Nov 2015 Data from this trial is expected to be published in a peer-reviewed journal in 2016, according to an Oxford BioMedica media release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top